TheraRadar
Data updated: Jun 17, 2026

ISOFLURANE

Trial Activity: Declining 2 active trials
Other Approved 1993-01-25

Isoflurane USP may be used for induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia. Isoflurane USP, a general anesthetic, is an inhalation agent indicated for induction and maintenance of general anesthesia.

Source: FDA Label • WATSON LABS

Development Insights

Sedana Medical conducting 3 trials (14%)
21 indications explored (Broad Platform)
sedation (4 trials)
mitral valve insufficiency (3 trials)
aortic valve insufficiency (3 trials)
6
Indications
--
Phase 3 Trials
33
Years on Market

Details

Status
Discontinued
First Approved
1993-01-25
Routes
INHALATION
Dosage Forms
LIQUID

ISOFLURANE Approval History

1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
48 FDA actions from 1993 to 2025
Nov 2025 ORIGINAL
Update
Jul 2024 SUPPL
Label · Labeling
Jan 2024 SUPPL
Label · Labeling

What ISOFLURANE Treats

6 FDA approvals

Originally approved for its first indication in 1993 . Covers 6 distinct patient populations.

  • Other (6)
📋

Clinical Trial Registry

22 trials
Trial Sponsor ID Phase Status Title
NCT05312385 INSPiRE-ICU1 results posted SED003 Ph 3 completed Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)
NCT05327296 INSPiRE-ICU2 results posted SED004 Ph 3 completed Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)
NCT07000526 IS-CRITIC HULP6844 2024-518521-14-00 Ph 4 recruiting Inhaled Sedation in Critically Ill Patients
NCT06624592 24-002252 Ph 3 recruiting Sevoflurane/Dexmedetomidine vs. Isoflurane for Pediatric Emergence Delirium
NCT04684238 IsoCOMFORT results posted SED002 Ph 3 completed Effect & Safety of Inhaled Isoflurane vs IV Midazolam for Sedation in Mechanically Ventilated Children 3-17 Years Old
NCT03588429 2018CZTCWM Ph 3 completed The Ratio of Hypnotic to Analgesic Potency of Volatile Anesthetics
NCT05314569 N-11-2022 Ph 1 completed Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open Heart Surgery in Pediatrics
NCT03569085 PRO17080624 Ph 1 completed Inhaled Anesthetics and Myocardial Strain
NCT05742789 6 Ph 1 completed Effect of Anesthetics on Troponin I and С-reactive Protein
NCT05696509 AMU3 Ph 3 completed Influence of Anesthetics on Clinical Outcome in Mitral and Aortic Valve Replacement in Adults
NCT05695287 10 Ph 1 completed The Effects of Sevoflurane, Isoflurane and Propofol During Cardiac Surgery
NCT02111447 results posted 412889-6 Ph 4 terminated Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI
NCT02925611 results posted 10313/PG-2Trg/2015/5408-9 Ph 4 completed Comparison of Postoperative Delirium in Patients Anaesthetised With Isoflurane and Desflurane During Spinal Surgery
NCT03146104 PGRMC-27.10.2016/29 Ph 4 completed Comparison of Total Intravenous Anesthesia vs. Inhalational Anesthesia in Acute Subdural Hematoma Patients
NCT02512809 results posted IRB14-00625 Ph 3 terminated Isoflurane-induced Neuroinflammation in Children With Hydrocephalus
NCT01397331 SHEBA-09-7199-SP-CTIL Ph 4 terminated Influence of Anesthesia on Mechanical Efficiency of Left Ventricle in Patients Undergoing Open Heart Surgery
NCT03373266 IRB0000871242 Ph 2 completed Serun Fluoride and Kidney Transplant
NCT00830843 GAS-SAH 1-citerio Ph 4 completed Inhalatorial Sedation in Patient With Subarachnoid Hemorrhage (SAH) Versus Conventional Intravenous Sedation
NCT01839084 PaNeX 12-051 2012-005698-30 Ph 3 completed PaNeX: Partial Nephrectomy Under Xenon
NCT01640275 MAD-PIA Pro00030861 Ph 1 completed Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia
NCT01601795 BS-57/12 Fassl_57/12 Ph 4 completed Sevoflurane and Isoflurane - During Cardiopulmonary Bypass With the MECC System (Minimized Extracorporeal Circuit)
NCT06014138 ISO-DRIVE SMRG_318537 Ph 2, Ph 3 recruiting Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ISOFLURANE FDA Label Details

Indications & Usage

Isoflurane USP may be used for induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia. Isoflurane USP, a general anesthetic, is an inhalation agent indicated for induction and maintenance of general anesthesia.

Looking for the branded version?

FORANE

Full clinical data, patents, trials, and competitive landscape for isoflurane.

See FORANE

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment